Articles

Poll

Podcasts

Slideshows

Videos

Dermatology

The HCPLive dermatology page is a resource for medical news and expert insights on skin disease. This page features expert-led coverage, articles, videos and research on the therapies and development of treatments for dermatologic conditions, and more.

Survey Highlights Inconsistencies in Toe Joint Scoring for PsA 66/68 Count

An observational study has indicated a correlation between biologic medications and a lower risk of CVD: more research is needed to determine causality.

Biologic Psoriasis Treatments May Have Lower Cardiovascular Disease Risk than Oral

This analysis suggests that exposures prior to, during, and following migration, along with structural factors are linked to skin health outcomes in migrant populations.

Gaps in Knowledge Identified Regarding Skin Health Outcomes in Migrant Populations

Without estrogen, the skin barrier weakens, leading to more severe and symptomatic psoriasis.

Menopause May Worsen Symptoms of Psoriasis, New Study Reveals

This analysis pointed to increased costs of biologics given the initiation of newer IL-17 and IL-23 inhibitors, suggesting the use of lower-cost options.

Study Finds Costs of Biologic Drugs for Psoriasis Rose Between 2007 to 2021

Anti-IL-17 medications meant to treat psoriasis and psoriatic arthritis may inadvertently harm gastrointestinal tract.

IL-17 Inhibitors May Raise Inflammatory Bowel Disease Risk, New Study Suggests

These findings highlight the impact of guselkumab on liver fibrosis progression among individuals living with psoriasis.

Guselkumab Not Linked to Worsening Liver Fibrosis in Psoriasis, 3-Year Study Finds

Ustekinumab and its generic biofamailiar SYSA1902 exhibited clinical equivalence in terms of safety, efficacy, pharmacokinetics, and immunogenicity.

SYSA1902 Clinically Equivalent to Ustekinumab for Plaque Psoriasis

Test your knowledge below on pooled data from the ADORING trial program and stay up to date with clinical advancements in atopic dermatitis.

Clinical Quiz: ADORING Trial and Tapinarof Cream for Atopic Dermatitis

The interchangeable designation was granted to CT-P17, a biosimilar to adalimumab (Humira), for inflammatory diseases such as psoriasis. 

FDA Grants Interchangeable Designation to Adalimumab Biosimilar CT-P17 (Yuflyma)

The HCPLive plaque psoriasis page is a resource for medical news and expert insights on psoriasis. This page features expert-led coverage, articles, videos and research on the therapies and development of treatments for psoriatic disease, and more.